Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Cerebrospinal fluid detection of interleukin-1beta in phase of remission predicts disease progression in multiple sclerosis.
Metabolomic profiling in multiple sclerosis: insights into biomarkers and pathogenesis.
DQB1*0602 rather than DRB1*1501 confers susceptibility to multiple sclerosis-like disease induced by proteolipid protein (PLP).
Response to "Glucocorticoids for treating Takotsubo syndrome?" and "Atypical global Takotsubo syndrome in a patient with acute disseminated encephalomyelitis".
Santhera Receives European Marketing Authorization for Raxone® in Leber's Hereditary Optic Neuropathy (LHON)
Posterior reversible encephalopathy syndrome masquerading as progressive multifocal leukoencephalopathy in rituximab treated neuromyelitis optica.
PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update.
High levels of cerebrospinal fluid free kappa chains predict conversion to multiple sclerosis.
Death receptor 6 negatively regulates oligodendrocyte survival, maturation and myelination.
Cladribine inhibits cytokine secretion by T cells independently of deoxycytidine kinase activity.
Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma.
Effects of functional electrical stimulation on gait function and quality of life for people with multiple sclerosis taking dalfampridine.
TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis.
A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta.
The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.
Age-dependent effects on the treatment response of natalizumab in MS patients.
Improving Hand Functional Use in Subjects with Multiple Sclerosis Using a Musical Keyboard: A Randomized Controlled Trial.
Expression of IL-33 and its epigenetic regulation in Multiple Sclerosis.
Focused suggestion with somatic anchoring technique: rapid self-hypnosis for pain management.
Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010.
Natalizumab in the treatment of rheumatoid arthritis in subjects receiving methotrexate
Detection of MicroRNAs in Microglia by Real-time PCR in Normal CNS and During Neuroinflammation.
Dried Blood Spot Methodology in Combination With Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of Teriflunomide.
Birth outcomes of pregnancies fathered by men with multiple sclerosis.
Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: a 24-week, controlled pilot study.
Pages
« first
‹ previous
…
158
159
160
161
162
163
164
165
166
…
next ›
last »